MétaCan
Menu
← Back to cohort

Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface GRP78.

2019· article· en· W2921242416 on OpenAlexaff
Ali Al‐Hashimi, Kevin Doyoon Won, Elizabeth Pham, Natalie F. Mariano, Julie M. Bailis, Richard C. Austin, Bobby Shayegan

Bibliographic record

VenueJournal of Clinical Oncology · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicEndoplasmic Reticulum Stress and Disease
Canadian institutionsJuravinski Cancer CentreMcMaster University
Fundersnot available
KeywordsDU145Unfolded protein responseEndoplasmic reticulumMedicineDownregulation and upregulationAntibodyCancer researchProstate cancerCell cultureCellMolecular biologyCancerLNCaPImmunologyCell biologyBiologyBiochemistryInternal medicineGene

Abstract

fetched live from OpenAlex

206 Background: Prostate cancer (PCa) is characterized by increased activation of the procoagulant protein, tissue factor (TF) that drive tumour progression. We now show that this process is modulated by GRP78 on the cell surface (cs). In PCa GRP78 is a endoplasmic reticulum-resident chaperone that localizes to the cell surface where it functions as a signaling molecule with antigenic properties. In response to csGRP78 presentation, PCa patients produce autoantibodies (AutoAbs) against the N-terminus of GRP78. AutoAbs:csGRP78 complex acts as a potent driver of tumor growth via upregulation of the unfolded protein response (UPR) and TF activity. We hypothesize that inhibiting the binding of anti-GRP78 AutoAbs to csGRP78 will supress UPR and TF activity. Here we describe a recombinant anti-GRP78 antibody (AEP8587) that competes with the binding of AutoAbs to csGRP78 and may act as a novel therapeutic antibody with antitumor activity. Methods: Changes in TF activity or UPR markers were evaluated in vitro in the PCa cell line DU145 following treatment with anti-GRP78 AutoAbs or co-treatment with either enoxaparin, a low molecular weight heparin (LMWH), or AEP8587. Protein expression of TF and UPR markers was determined using western blotting and qRT-PCR. TF activity was determined using a real-time continuous assay. AutoAbs were purified PCa patients (St. Joseph’s Healthcare Hamilton). Results: Pre-prostatectomy PCa patients display high levels of anti-GRP78 AutoAbs (~60µg/ml), compared to healthy controls (~5µg/ml). Here, we show that anti-GRP78 AutoAb increases TF activation in vitro and leads to increased tumor progression in a DU145 xenograft model. In contrast, we show a co-treatment of anti-GRP78 AutoAb with either enoxaparin or AEP8587 completely abolishes the AutoAb-mediated increase in TF activity in vitro. Enoxaparin or AEP8587 co-treatment reversed the AutoAb effect on increased UPR markers. Conclusions: We have identified anti-GRP78 AutoAb as a driver of PCa progression. Our results indicate that a recombinant antibody, AEP8587, can bind to csGRP78 and prevent the binding of anti-GRP78 AutoAbs. This represents a potential novel means to manage PCa progression.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.427
Teacher spread0.395 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicEndoplasmic Reticulum Stress and Disease→French-language works237,207→